Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
Financials
Financial year 2024
EXIM PHARMA from Elsene, company number BE0773362489, closed financial year 2024 with a result of € -131,949 after tax. For that financial year EXIM PHARMA recorded a gross margin of € -65,144 and equity of € -356,086. Compared with financial year 2023, the result moved from € -160,090 to € -131,949. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2025.
€ -356,086
▼ € 131,949 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -131,949
▲ 18 % less loss than in 2023
Profit after tax over the fiscal year.
€ 29,142
▲ 190% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -406,086.
People and assets in 2024
€ 65,148
▲ 19% vs 2023
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 561,600
▲ 86% vs 2023
Loans from banks and other lenders, long and short.
€ 42,324
▲ 18% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 4,705
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|
| Gross margin | € -113,569 | € -104,358 | € -65,144 | ▲ € 39,214 |
| Profit after taxes | € -114,047 | € -160,090 | € -131,949 | ▲ € 28,141 |
| Equity | € -64,047 | € -224,137 | € -356,086 | ▼ € 131,949 |
| Total debts | € 116,127 | € 337,608 | € 608,629 | ▲ 80% |
| Cash | € 43,099 | € 10,049 | € 29,142 | ▲ 190% |
| Retained profit | € -114,047 | € -274,137 | € -406,086 | ▼ € 131,949 |
| Bank debt | € 110,000 | € 301,600 | € 561,600 | ▲ 86% |
| Balance sheet total | € 52,080 | € 113,472 | € 252,543 | ▲ 123% |
Key figures of EXIM PHARMA, fiscal years 2022 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to EXIM PHARMA?
What happened at EXIM PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 131,949. filed late Source: NBB ↗
- CHRISTIAN DEPREZ CONSULTING BV became a director. NBB
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
In short
From € 114,047 loss in 2022 to € 131,949 loss in 2024.
Paid € 128 in corporate taxes since 2022.
A new publication or filing at EXIM PHARMA? We notify you, reason included.
Follow EXIM PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of SCORPIAUX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
EXIM PHARMABehind EXIM PHARMA is CHRISTIAN DEPREZ CONSULTING BV. The shares are held by SCORPIAUX (25%).
Directors
According to the 2024 annual accounts
CHRISTIAN DEPREZ CONSULTING BV
Director · represented by Christian DEPREZ
Also active at: Swiftpharma
since 2024
Shareholders
25%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Louizalaan 231
1050 Elsene
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
DNS
TransIP DNS
Website info
Features
Security
Details
- Company number
- 0773.362.489
- VAT number
- BE 0773.362.489
- Registered office
- Louizalaan 231, 1050 Elsene
- Names & denominations
- EXIM PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 31 August 2021
- Peppol
- Active · Active since 1 Dec 2025
- Contact
- eximpharma.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in andere voedingsmiddelen, neg
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Groothandel in parfumerieën en cosmetica
Groothandel in andere machines en werktuigen, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Groothandel in andere machines en werktuigen, n.e.g.